Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | PARACHUTE trial: ATG in HCST

Jaap Jan Boelens • 1 Sep 2020
EBMT 2020
General Anti-thymocyte globulin
PARACHUTE

Jaap Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the PARACHUTE-trial (NTR4960), involving anti-thymocyte globulin (ATG) introduction into the conditioning regimen in hematopoietic stem cell transplantation (HSCT) to prevent graft-versus-host-disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jaap Jan Boelens

4:54
Predicting immune reconstitution following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
3:20
Second cord blood transplant for patients who relapse following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
4:53
The influence of the pulmonary microbiome on outcomes after alloHSCT
Jaap Jan Boelens • 24 Apr 2022
3:40
CD4+ T-cell reconstitution in allo-HSCT settings
Jaap Jan Boelens • 24 Aug 2020

Related Videos

2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:12
The contribution of viral infections, such as EBV, to post-transplant lymphoproliferative disease
Susan Prockop • 16 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
The content of VJHemOnc is intended for healthcare professionals